Thomas Dayspring: A Decade on Repatha – Stable CAD, No Ischemic Events
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Anecdotal Study of 1 — Me — I have chronic stable CAD (CAC > 300 15 years ago). With that and other risk factors I had, I easily would have qualified for inclusion in the VESALIUS CV Trial. Fortunately, as soon as PCSK9i came on the market I went on Repatha and now a decade later I am still here – no ischemic events. The day after I got the CAC, I had an invasive coronary angiogram which demonstrated wide open lumens: disease was all in arterial wall. Here is data from GLACOV that shows evolocumab not only kept me alive without any CV issues but likely is causing regression. My apoB on Repatha monotherapy is 50 mg/dL and LDL-C 45 mg/dL. THANK YOU REPATHA, Amgen National Lipid Association European Atherosclerosis Society, American Society for Preventive Cardiology (ASPC).”
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy